Motoko Kimura

Motoko Kimura


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2017 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
MKMotoko Kimura
Motoko Kimura
KHKoji Hayashizaki
Koji Hayashizaki
KTKoji Tokoyoda
Koji Tokoyoda
STShiki Takamura
Shiki Takamura
SMShinichiro Motohashi
Shinichiro Motohashi
TNToshinori Nakayama
Toshinori Nakayama

11 June 2022 in International Immunology
Verified
Journal Article
Open access
PDF file
RKRyo Koyama-Nasu
Ryo Koyama-Nasu
YWYangsong Wang
Yangsong Wang
IHIchita Hasegawa
Ichita Hasegawa
YEYukihiro Endo
Yukihiro Endo
TNToshinori Nakayama
Toshinori Nakayama
MKMotoko Kimura
Motoko Kimura
Cancer immunotherapy utilizes our immune system to attack cancer cells and is an extremely promising strategy for cancer treatment. Although immune-checkpoint blockade, such as anti-PD-1 (programmed cell death 1) antibody, has demonstrated significant enhancement of anti-tumor immunity and has induced notable clinical outcomes, its response rates remain low, and adverse effects are always a matter of concern; therefore, new targets for cancer immunotherapy are always desired. In this situation, new concepts are needed to fuel the investigation of new target molecules for cancer immunotherapy. We propose that CD69 is one such target molecule. CD69 is known to be an activation marker of leukocytes and is also considered a crucial regulator of various immune responses through its interacting proteins. CD69 promotes T-cell retention in lymphoid tissues via sphingosine-1-phosphate receptor 1 (S1P1) internalization and also plays roles in the pathogenesis of inflammatory disorders through interacting with its functional ligands Myl9/12 (myosin light chains 9, 12a and 12b). In anti-tumor immunity, CD69 is known to be expressed on T cells in the tumor microenvironment (TME) and tumor-draining lymph nodes (TDLNs). We revealed that CD69 negatively regulates the effector function of intratumoral T cells and importantly controls the ‘exhaustion’ of CD8 T cells. In addition, we and others showed that either CD69 deficiency or the administration of anti-CD69 monoclonal antibody enhances anti-tumor immunity. Thus, CD69 is an attractive target for cancer immunotherapy.

5 April 2019 in Seminars in Immunopathology
Verified
Journal Article
Closed access
PDF file
MKMotoko Kimura
Motoko Kimura
RKRyo Koyama-Nasu
Ryo Koyama-Nasu
RYRyoji Yagi
Ryoji Yagi
TNToshinori Nakayama
Toshinori Nakayama

26 September 2016 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
MKMotoko Kimura
Motoko Kimura
JTJulien Thomas
Julien Thomas
XTXuguang Tai
Xuguang Tai
TGTerry I Guinter
Terry I Guinter
MSMiho Shinzawa
Miho Shinzawa
ASAlfred Singer
Alfred Singer

22 May 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
RKRyo Koyama-Nasu
Ryo Koyama-Nasu
MKMotoko Kimura
Motoko Kimura
MKMasahiro Kiuchi
Masahiro Kiuchi
AAAmi Aoki
Ami Aoki
YWYangsong Wang
Yangsong Wang
TNToshinori Nakayama
Toshinori Nakayama
Tumor-specific CD8+ T cells play a pivotal role in antitumor immunity and are a key target of immunotherapeutic approaches. Intratumoral CD8+ T cells are heterogeneous; Tcf1+ stemlike CD8+ T cells give rise to their cytotoxic progeny—Tim-3+ terminally differentiated CD8+ T cells. However, where and how this differentiation process occurs has not been elucidated. We herein show that terminally differentiated CD8+ T cells can be generated within tumor-draining lymph nodes (TDLN) and that CD69 expression on tumor-specific CD8+ T cells controls its differentiation process through regulating the expression of the transcription factor TOX. In TDLNs, CD69 deficiency diminished TOX expression in tumor-specific CD8+ T cells, and consequently promoted generation of functional terminally differentiated CD8+ T cells. Anti-CD69 administration promoted the generation of terminally differentiated CD8+ T cells, and the combined use of anti-CD69 and anti–programmed cell death protein 1 (PD-1) showed an efficient antitumor effect. Thus, CD69 is an attractive target for cancer immunotherapy that synergizes with immune checkpoint blockade.

27 July 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CIChiaki Iwamura
Chiaki Iwamura
KHKiyoshi Hirahara
Kiyoshi Hirahara
MKMasahiro Kiuchi
Masahiro Kiuchi
SISanae Ikehara
Sanae Ikehara
KAKazuhiko Azuma
Kazuhiko Azuma
TNToshinori Nakayama
Toshinori Nakayama
The mortality of coronavirus disease 2019 (COVID-19) is strongly correlated with pulmonary vascular pathology accompanied by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection–triggered immune dysregulation and aberrant activation of platelets. We combined histological analyses using field emission scanning electron microscopy with energy-dispersive X-ray spectroscopy analyses of the lungs from autopsy samples and single-cell RNA sequencing of peripheral blood mononuclear cells to investigate the pathogenesis of vasculitis and immunothrombosis in COVID-19. We found that SARS-CoV-2 accumulated in the pulmonary vessels, causing exudative vasculitis accompanied by the emergence of thrombospondin-1–expressing noncanonical monocytes and the formation of myosin light chain 9 (Myl9)–containing microthrombi in the lung of COVID-19 patients with fatal disease. The amount of plasma Myl9 in COVID-19 was correlated with the clinical severity, and measuring plasma Myl9 together with other markers allowed us to predict the severity of the disease more accurately. This study provides detailed insight into the pathogenesis of vasculitis and immunothrombosis, which may lead to optimal medical treatment for COVID-19.